Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication.

Here, we compare the risk/benefit profiles of three leading oral antiviral drugs: Favipiravir, Molnupiravir, and Paxlovid. These compounds have distinct features supporting their targeted use by persons with COVID-19 disease.

Avifavir, the first direct oral antiviral drug was registered in Indonesia under an accelerated procedure based on data of the GCP phase II-III clinical trial conducted in 30 clinical centers in April-September 2020 involving 460 patients.